Reunion Neuroscience Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression
23 juil. 2024 07h30 HE
|
Reunion Neuroscience Inc.
MORRISTOWN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today announced that...
Reunion Neuroscience Announces Publication of Results from Early Preclinical Studies Demonstrating the Potential of RE104 for Development in Depressive Disorders
20 mai 2024 07h30 HE
|
Reunion Neuroscience Inc.
Reunion’s lead asset, RE104, is a potential best-in-class, clinical-stage serotonergic psychedelic drug candidate designed as a safe, fast-acting, short duration therapy to provide lasting benefits to...
Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings
02 mai 2024 06h30 HE
|
Reunion Neuroscience Inc.
Company is advancing RE104, its proprietary, clinical-stage serotonergic psychedelic drug candidate designed as a safe, fast-acting, short duration therapy to provide lasting benefits to patients with...
Reunion Neuroscience Inc. Announces Upcoming Presentations at the Anxiety and Depression Association of America (ADAA) 2024 Conference
03 avr. 2024 07h30 HE
|
Reunion Neuroscience Inc.
MORRISTOWN, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today...
Reunion Neuroscience Inc. to Participate in October Investor Conferences
05 oct. 2023 07h30 HE
|
Reunion Neuroscience Inc.
WILMINGTON, N.C., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic...
Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate a Phase 2 Study of RE104 for the Treatment of Postpartum Depression
18 sept. 2023 07h30 HE
|
Reunion Neuroscience Inc.
WILMINGTON, Del., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for...
Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement
01 août 2023 09h03 HE
|
Reunion Neuroscience Inc.
TORONTO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing...
Reunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan of Arrangement
14 juil. 2023 16h05 HE
|
Reunion Neuroscience Inc.
TORONTO, July 14, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing...
Reunion Neuroscience Inc. Shareholders Approve Proposed Plan of Arrangement
13 juil. 2023 07h30 HE
|
Reunion Neuroscience Inc.
TORONTO, July 13, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the “Company”), a clinical-stage biopharmaceutical company committed to developing...
Reunion Neuroscience Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
29 juin 2023 07h30 HE
|
Reunion Neuroscience Inc.
Common Shareholders to Receive Consideration of US$1.12 Per Share in Cash from the Arrangement Agreement with MPM BioImpact; Special Shareholder Meeting Scheduled July 12 Presented Encouraging Phase...